Erratum to: Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis [Immunologic Research, (2015), 61, 24-30, 10.1007/s12026-014-8560-x];Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis

Immunologic Research

Volumn 61, Issue 1-2, 2015, Pages 24-30

  Yee, Alvin ^a   Webb, Tyler ^a   Seaman, Andrea ^a   Infantino, Maria ^b   Meacci, Francesca ^b   Manfredi, Mariangela ^b   Benucci, Maurizio ^b   Lakos, Gabriella ^a   Favalli, Ennio ^c   Shioppo, Tommaso ^c   Meroni, Pier Luigi ^c   Mahler, Michael ^a  

^a INOVA DIAGNOSTICS INC   (United States)

^b UO Allergologia Immunologia Clinica   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Autoantibodies; CarP; CCP; Citrullinated cyclic peptide; Homocitrulline; RA; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL MARKER; CARBAMYLATED PROTEIN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; AUTOANTIGEN; DIAGNOSTIC KIT;

ANTIBODY RESPONSE; ARTICLE; CARBAMOYLATION; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; FETAL CALF SERUM; HUMAN; IMMUNOASSAY; JOINT INJURY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; BLOOD; CROSS-SECTIONAL STUDY; DIAGNOSTIC KIT; IMMUNOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; HUMANS; PROGNOSIS; REAGENT KITS, DIAGNOSTIC; SEVERITY OF ILLNESS INDEX;

EID: 84925518142     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-015-8642-4     Document Type: Erratum

References (28)

1. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol. 2011;7:391–8.
2. Wiik AS, van Venrooij WJ, Pruijn GJ. All you wanted to know about anti-CCP but were afraid to ask. Autoimmun Rev. 2010;10:90–3.
3. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101:273–81.
4. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.
5. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8.
6. Kessenbrock K, Raijmakers R, Fritzler MJ, Mahler M. Synthetic peptides: the future of patient management in systemic rheumatic diseases? Curr Med Chem. 2007;14:2831–8.
7. Levesque MC, Zhou Z, Moreland LW. Anti-cyclic citrullinated peptide testing for the diagnosis of rheumatoid arthritis and the quest for improved sensitivity and predictive value. Arthritis Rheum. 2009;60:2211–5.
8. van Venrooij WJ, Zendman AJ, Pruijn GJ. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev. 2006;6:37–41.
9. Trouw LA, Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev. 2012;12:318–22.
10. Willemze A, Bohringer S, Knevel R, et al. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis. 2012;71:268–74.
11. Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA. 2011;108:17372–7.
12. Shi J, van de Stadt LA, Levarht EW, et al. Anti Carbamylated Protein antibodies (anti-CarP) are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum. 2013;65:911–5.
13. Shi J, Willemze A, Janssen GM, et al. Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the ‘AMC-Senshu’ method. Ann Rheum Dis. 2013;72:148–50.
14. Shi J, van Veelen PA, Mahler M, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev. 2014;13:225–30.
15. Jiang X, Trouw LA, van Wesemael TJ, et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis. 2014;73:1761–8.
16. Kok MB, Tegelaers FP, van Dam B, van Rijn JL, van Pelt J. Carbamylation of albumin is a cause for discrepancies between albumin assays. Clin Chim Acta. 2014;434:6–10.
17. Scinocca M, Bell DA, Pope J, Cairns E, Barra L. Rheumatoid arthritis patients have anti-homocitrullinated fibrinogen antibodies. Arthritis Rheum. 2012;63:850.
18. Scinocca M, Bell DA, Racape M, et al. Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. J Rheumatol. 2014;41:270–9.
19. Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014;73:780–3.
20. van Riel PL, Schumacher HR Jr. How does one assess early rheumatoid arthritis in daily clinical practice? Best Pract Res Clin Rheumatol. 2001;15:67–76.
21. van der Heijde D, Kalden J, Scott D, Smolen J, Strand V. Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann Rheum Dis. 2004;63:737–9.
22. Silveira IG, Burlingame RW, von Muhlen CA, Bender AL, Staub HL. Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol. 2007;26:1883–9.
23. Bossuyt X, Coenen D, Fieuws S, et al. Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor. Ann Rheum Dis. 2009;68:287–9.
24. Somers K, Geusens P, Elewaut D, et al. Novel autoantibody markers for early and seronegative rheumatoid arthritis. J Autoimmun. 2011;36:33–46.
25. Kokkonen H, Mullazehi M, Berglin E, et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther. 2011;13:R13.
26. Rakieh C, Nam JL, Hunt L, et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2014-205227.
27. Conrad K, Roggenbuck D, Reinhold D, Dorner T. Profiling of rheumatoid arthritis associated autoantibodies. Autoimmun Rev. 2010;9:431–5.
28. Courvoisier N, Dougados M, Cantagrel A, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2008;10:R106.